Triton Logistics & Maritime is aiming to increase its turnover to Rs 500 crore from the current Rs 150 crore in the next two to three years, its CEO Jitendra Srivastava said on Friday. "Triton is still in a very early stage. Right now, we're touching around Rs 150 crore in turnover. The aim is to scale this up to Rs 500 crore in the next two to three years," the CEO said. The company which specialises in freight forwarding, logistics, and global supply chain management with end-to-end solutions plans to scale up its turnover by investing into a lot of services and solutions, he said. "Our business plan is focused around two main pillars - geography and industry. On one hand, we are looking at which geographies we want to expand into, on the other hand, we are identifying industries where we can deliver tailored solutions," he explained. Apart from that, the company is putting a lot of effort into digitalisation and that's a major area where Triton Logistics & Maritime is ...
Blue Jet Healthcare's stock was quoting at ₹715, up 4.32 per cent on the National Stock Exchange
Analysts believe that pharma shares continue to see buying interest, given the inelastic demand for medicines; tariffs, if any could have minimal impact on the industry.
A total of 11 pharma and healthcare-related stocks have rallied more than 20% thus far in April on hopes of a likely softer tariff-related stance by the US President Donald Trump.
DTAB has accepted sub-panel recommendation on OTC drugs list
An expert panel has recommended suspending ranitidine after tests found cancer-linked NDMA levels in half the samples, bringing India closer to a nationwide ban
Divi's Labs stock was quoting at ₹5,855.50, up 3.81 per cent from Thursday, April 17 close of ₹5,640
Administering the right dose for asset-light expansion and steady margins
To commercialise transcatheter aortic valve system in India, Europe and other select markets
Indian firms have been focusing on complex generics for some time now, which insulates them partially from pricing pressures in the generics space in the US
Nuvama Institutional Equities said therapies like antidiabetic, anti-infective and respiratory had underperformed in the Indian pharma market
Growth hormone kicks in as India's largest pharma firm's vital signs hold amid generic strain
A Russian missile struck a warehouse of an Indian pharmaceutical company in Ukraine on Saturday, the Ukrainian embassy in India said. In a social media post, the mission alleged that Moscow is deliberately targeting Indian businesses, destroying medicines meant for children and the elderly. "Today, a Russian missile struck the warehouse of Indian pharmaceutical company Kusum in Ukraine," the Ukrainian embassy said. "While claiming "special friendship" with India, Moscow deliberately targets Indian businesses -? destroying medicines meant for children and the elderly," it posted on X. No further details are immediately available.
According to market estimates, Leqselvi is projected to contribute $90 million to Sun Pharma's sales in FY26, and $125 million in FY27
However, on a weekly basis, the Sensex and Nifty posted a decline of 0.27 per cent and 0.33 per cent, respectively
Banking, financial services, and insurance (BFSI), telecom, and metals saw the highest FII flows in March 2025
The rise in the Biocon share price came after its wholly-owned unit, Biocon Pharma, received USFDA nod for Everolimus tablets.
Cipla said USFDA has approved the ANDA submitted for Paclitaxel Protein-bound Particles for Injectable Suspension (albumin-bound), 100 mg/vial, Single-Dose Vial ('Protein-bound Paclitaxel') on Apr 10
The rise in the Sun Pharma share price came after a favourable ruling from a US court regarding its planned launch of Leqselvi (deuruxolitinib).
The AEO programme is implemented by the Central Board of Indirect Taxes and Customs (CBIC) under the aegis of the World Customs Organization's SAFE Framework